UCL to harness Synpromics’ promotors in gene therapy collaboration – BioPharma-Reporter.com
BioPharma-Reporter.com |
UCL to harness Synpromics’ promotors in gene therapy collaboration
BioPharma-Reporter.com In gene therapy, synthetic promotors – used to regulate gene activity and precisely control protein production – deliver therapeutic genes to immune cells such as microglia, macrophages, and T-cells. Synpromics said the research collaboration provides … |
OncLive |
Other Immunotherapy Approaches in Gastric/GEJ Cancers
OncLive There’s also a host of new drug development focused on combining immunotherapy with targeted therapy, such as, in the case of gastric and GEJ cancer, HER2 inhibitors such as trastuzumab, pertuzumab, or some of the other HER2 inhibitors. And in … |
|
Gene therapy stocks tank after leading scientist reveals safety …
MarketWatch Shares of gene therapy companies fell sharply Tuesday, after a report by a prominent scientist revealed the safety concerns that led him to resign recently from Solid Bioscience Inc.’s SLDB, -17.00% scientific advisory board. Gene therapy researcher … |
Patch.com |
Batten Disease: Gene Therapy Offers Hope For Boulder Girl
Patch.com She giggles in excitement as she rides atop the therapy horse or splashes in the lake pretending to be a mermaid. And she never gets enough of her brother’s stories and jokes.” Amid all the devastating news came a glimmer of hope that, over the past … |
Endpoints News |
Gene therapy pioneer James Wilson sounds an alarm on high-dose AAV studies following toxic reactions in monkeys
Endpoints News Penn professor James Wilson is one of the preeminent scientists working today in gene therapy. He’s also the key figure in a fatal gene therapy trial back in the late ’90s that left the field in limbo for years, until a new generation of biotechs … Gene Therapy May Not Be a Viable Option for Many PatientsGenetic Engineering & Biotechnology News |